文献速递胸部病理细胞病理与分子病理

非小细胞肺癌酪氨酸激酶抑制剂获得性耐药:下一代测序在支气管内超声引导经支气管针吸样本中的作用

Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples.
PubMed 文献 · Arch Pathol Lab Med · 2018-01-01

本文综述了在非小细胞肺癌患者经EGFR/ALK酪氨酸激酶抑制剂治疗后进展时,利用支气管内超声引导经支气管针吸(EBUS-TBNA)细胞学样本进行下一代测序(NGS)分析以检测获得性耐药分子异常的实施情况。文章回顾了同行评议的原始论文、综述、指南和专家意见,并结合单中心经验,指出NGS分析和EBUS-TBNA操作可能是满足酪氨酸激酶抑制剂耐药非小细胞肺癌分子检测独特需求的有价值策略。

要点

  • EBUS-TBNA细胞学样本常是晚期非小细胞肺癌患者唯一可用的分子检测样本。
  • NGS分析EBUS-TBNA样本可用于检测EGFR/ALK TKI获得性耐药的分子异常。
  • 该策略在技术、生物学和临床层面面临独特挑战,但具有应用价值。

核心结论

  • NGS分析和EBUS-TBNA操作可能是满足TKI耐药NSCLC分子检测独特需求的有价值策略。

研究设计与样本

  • 综述同行评议原始论文、综述、指南和专家意见,并结合单中心经验。

主要发现

  • EBUS-TBNA细胞学样本常是晚期NSCLC患者唯一可用的样本。
  • 在EBUS-TBNA样本上实施NGS检测是肺细胞病理学正在发展的领域。
  • 对TKI耐药NSCLC应用分子分析带来独特的技术、生物学和临床挑战。

临床怎么用

  • 对EGFR/ALK TKI治疗进展的NSCLC患者,可考虑采用EBUS-TBNA样本进行NGS检测获得性耐药分子异常。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: - Molecular testing is essential for the diagnostic workup of patients with advanced non-small cell lung cancers. Cytology specimens from minimally invasive procedures, such as endobronchial ultrasound-guided transbronchial needle aspiration, are often the only available samples for these patients. The implementation of molecular diagnostic testing, and in particular next-generation sequencing-based testing, on these cytologic specimens is currently an evolving field for lung cytopathology. The application of these molecular analyses on tyrosine kinase inhibitor-resistant non-small cell lung cancers raises unique technical, biologic, and clinical challenges. OBJECTIVE: - To provide an overview of the implementation of next-generation sequencing analysis on endobronchial ultrasound-guided transbronchial needle aspiration samples to detect the molecular aberrations underneath the phenomenon of acquired resistance in patients with non-small cell lung cancers progressing while on the EGFR/ALK tyrosine kinase inhibitor treatment. DATA SOURCES: - Peer-reviewed original articles, review articles, and published guidelines and expert opinion reports were reviewed, together with our single-center experience. CONCLUSIONS: - Next-generation sequencing analyses and the endobronchial ultrasound-guided transbronchial needle aspiration procedure may represent a valuable strategy to address the unique requirements of molecular testing on tyrosine kinase inhibitor-resistant non-small cell lung cancers.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Guerini-Rocco E, Passaro A, Casadio C, et al. Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples. Arch Pathol Lab Med. 2018. PMID: 29565206. doi:10.5858/arpa.2017-0158-RA

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。